Saturday 17 October 2026
Export BCDA’s income statement to Excel — free account
BioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024. In the quarter to June 2026, EPS grew 67.5% and free cash flow fell 5.15%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.92
0.02
−2.13%
Follow BCDA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.02 | 0.35 | 1.03 | 1.60 | |
Current Ratio |
2.09 | 0.41 | 1.12 | 1.62 | |
Net Debt/EBITDA |
2.54 | 0.43 | 1.24 | 3.56 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.08 | 0.73 | 1.26 | 1.13 | |
Capex/Depreciation |
0.00 | (1.00) | (2.00) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.15) | (0.37) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.15) | (0.38) | (0.27) | |
Cash per Share |
0.34 | 0.09 | 0.37 | 0.84 | |
Shareholders Equity per Share |
0.22 | (0.10) | 0.13 | 0.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.22 | (0.10) | 0.13 | 0.42 | |
Free Cash Flow |
(1.73) | (1.66) | (2.50) | (1.67) | |
Working Capital |
2.24 | (1.64) | 0.30 | 2.06 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | 0.00 | |
Net Current Asset Value |
2.24 | (1.64) | 0.21 | 1.84 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | — | 0.04 | — | |
Average Payables |
0.89 | 0.82 | 0.51 | 0.82 | |
Average Assets |
3.42 | 1.94 | 3.57 | 6.21 | |
Average Common Equity |
0.41 | (1.29) | 0.87 | 2.69 |
Columns are period end dates